ATRCAtriCure, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though rich vs its sector.
Priced for ~19% a year FCF growth. Roughly in line with its three-year revenue growth of 16% a year.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ATRC's price assumes
AtriCure, Inc. trades at 281× earnings against 40.7× for the median Medical Instruments & Supplies name, more expensive than its own group.
Trailing P/E · Medical Instruments & Supplies median 40.7 · 6.91× the median: the market pays up for this one
- Price / sales
- 5.27
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 1.8%
Free cash flow yield · Medical Instruments & Supplies median 3.6%
- Growth the price implies
- +19%
Growth the price implies · The price pays for +19% free cash flow growth a year for a decade; revenue has grown 16% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 5.81
- EV / EBIToperating margin 2.3%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 5.08
- Healthcare median P/E503 names
- 27.9
- Medical Instruments & Supplies median P/E32 names
- 40.7
- Free cash flow, trailing twelve months
- $53M
- Market capitalisation50.9 million shares, counted Jul 22, 2026
- $3.00B
- 3-year revenue growth
- +16%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Medical Instruments & Supplies
Ranks #15 of 20 by RyuScore